Agilent Technologies has formed a life-sciences advisory board “to identify and evaluate technologies and applications” in the biotech sector, the company said last week.
“This is one more step toward accelerating our growth as a leading supplier of gene expression, proteomics and pharmaceutical analysis solutions,” Chris Van Ingen, general manager of Agilent’s life sciences and chemical analysis division, said in a statement.
Members of the board, which is expected to meet two or three times each year, include Paul Herring, director of corporate research at Novartis International; Anthony Martin, president and CEO of Molecular Probes; Mark Skolnick, founder of Myriad Genetics; and, Wendell Wierenga, CEO of Syrrx.
Ardais has appointed to its scientific advisory board Todd Golub, director for cancer genomics at the Whitehead/MIT Center for Genome Research.
As head of cancer genomics, Golub focuses on “discovering genomic and computational solutions to problems” in cancer biology and cancer medicine, including developing new strategies for the diagnosis and treatment of cancer.
Golub, who is also a pediatric oncologist at Dana-Farber Cancer Institute, received his MD from the University of Chicago Pritzker School of Medicine and pursued clinical training in pediatric oncology at Boston Children’s Hospital and the Dana-Farber Cancer Institute. He completed his postdoctoral research training at the Brigham and Women’s Hospital and Harvard Medical School.
ParAllele BioScience last week appointed Applied Biosystems co-founder Andre Marion to its board of directors.
Marion served as chairman, CEO, and president of ABI for several years until the company’s merger with Perkin Elmer. In 1995 Marion retired from Perkin Elmer as president of its ABI division.
Marion held various R&D management positions with Hewlett-Packard. He currently serves as a director on the boards of Aclara BioSciences, Molecular Devices, Cygnus, and Applied Imaging.